Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | Met |
| Gene Name: | MET |
| Protein Full Name: | Hepatocyte growth factor receptor |
| Alias: | C-met; EC 2.7.10.1; Hepatocyte growth factor receptor; HGF receptor; HGFR; HGF-SF receptor; Kinase Met; Met proto- oncogene tyrosine kinase; Met proto-oncogene; Met proto-oncogene (hepatocyte growth factor receptor); RCCP2 |
| Mass (Da): | 155541 |
| Number AA: | 1390 |
| UniProt ID: | P08581; A1L467; Q14825; Q9UEJ3; E6Y365; Q59EB3 |
| Locus ID: | 4233 |
| COSMIC ID: | MET |
| Gene location on chromosome: | 7q31 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 31494 |
| Percent of cancer specimens with mutations: | 1.71 |
| General distribution of mutations: | Multi-site |
| Location of most mutations: | Broad distribution of mutation sites with many point mutations, but only 6 deletions at AA 982; no other complex mutations, insertions and deletions across the entire protein. However, point mutations at AA 1253 occurs at a very much higher frequency than |
| Commonly recorded point mutations: | Y1253D (47); T1010I (41); Y1248C (9) |
| Mutations observed as inherited: | Hereditary papillary renal cancer (HPRC). Non-hereditary: renal papillary cancer. |
| Found in amplified chromosomal regions in human cancers: | Gastric carcinomas (20%) |
| Deregulated in translocations: | Fusion partners include Tpr. |
| Normal role description: | MET is a receptor-tyrosine kinase that is activated upon binding hepatocyte growth factor (HGF). MET/HGF signalling has been implicated in the generation and progression of a variety of tumors. The coexpression of wild type MET and HGF in the same cell (which generates an autocrine stimulatory loop) induces oncogenic transformation. All investigated naturally occurring MET mutants show increased tyrosine phosphorylation level and enhanced kinase activity |
| Commentary on involvement of protein in cancer: | Y1253 is located in the kinase catalytic domain in the kinase activation loop just after subdomain VII. |